Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | AXL over exp BRAF V600E |
| Therapy | Bemcentinib + Vemurafenib |
| Indication/Tumor Type | melanoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| AXL over exp BRAF V600E | melanoma | sensitive | Bemcentinib + Vemurafenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Bemcentinib (BGB-324) and Zelboraf (vemurafenib) combination treatment synergistically inhibited viability of melanoma cell lines harboring BRAF V600E and overexpressing Axl in culture, and resulted in improved tumor growth inhibition and tumor regression over either agent alone in a cell line xenograft model (PMID: 35332208). | 35332208 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35332208) | AXL inhibition improves BRAF-targeted treatment in melanoma. | Full reference... |